| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 01/20/2011 | US20110014227 Pre-or post-exposure treatment for filovirus or arenavirus infection |
| 01/20/2011 | US20110014226 high throughput protein interaction assay |
| 01/20/2011 | US20110014225 Cross-reactive determinants and methods for their identification |
| 01/20/2011 | US20110014224 Methods for producing an immune response to tuberculosis |
| 01/20/2011 | US20110014222 Stereoisomer Peptides and Their Polymer Conjugates for HIV Disease |
| 01/20/2011 | US20110014220 Human respiratory syncytial virus (rsv) vaccine |
| 01/20/2011 | US20110014219 Norovirus and Sapovirus antigens |
| 01/20/2011 | US20110014211 Composition for neutralizing botulinus toxin type-a, and human anti-botulinus toxin type-a antibody |
| 01/20/2011 | US20110014210 Chlamydia vaccine |
| 01/20/2011 | US20110014209 Recombinant hcv e2 glycoprotein |
| 01/20/2011 | US20110014187 Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes |
| 01/20/2011 | US20110014184 Inactivating organisms using carbon dioxide at or near its supercritical pressure and temperature conditions |
| 01/20/2011 | US20110014178 Antimicrobial Composition and Method for Use |
| 01/20/2011 | US20110014157 Method for producing a mixture of bacteriophages and the use thereof in the therapy of antibiotic-resistant staphylococci |
| 01/20/2011 | US20110014155 Reovirus for the Treatment of Cellular Proliferative Disorders |
| 01/20/2011 | US20110014154 Aromatic Heterocyclic Fused Indolobenzadiazepine HCV NS5B Inhibitors |
| 01/20/2011 | US20110014123 RNA interference mediating small RNA molecules |
| 01/20/2011 | CA2768291A1 3-hydroxypyrrolidine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase |
| 01/20/2011 | CA2768204A1 Gram-positive bacteria specific binding compounds |
| 01/20/2011 | CA2768149A1 Stereoisomer peptides and their polymer conjugates for hiv disease |
| 01/20/2011 | CA2768081A1 Anti-influenza agents |
| 01/20/2011 | CA2768018A1 Pharmaceutical for oral delivery comprising mgbg and methods of treating disease |
| 01/20/2011 | CA2767642A1 Lupeol-type triterpene derivatives as antivirals |
| 01/20/2011 | CA2767614A1 Fusidic acid dosing regimens for treatment of bacterial infections |
| 01/20/2011 | CA2767453A1 2,3-fluorinated glycosides as neuraminidase inhibitors and their use as anti-virals |
| 01/20/2011 | CA2765942A1 Flavin derivatives |
| 01/19/2011 | EP2275818A2 Method for improved early recognition of the seroconversion of an antibody to hepatitis C |
| 01/19/2011 | EP2275557A1 Albumin fusion proteins |
| 01/19/2011 | EP2275548A1 Mammalian cytokine receptor subunit proteins, related reagents and methods |
| 01/19/2011 | EP2275546A2 Enzymatic DNA molecules |
| 01/19/2011 | EP2275535A1 Animal cells and processes for the replication of influenza viruses |
| 01/19/2011 | EP2275441A1 High affinity HIV T cell receptors |
| 01/19/2011 | EP2275424A1 Doripenem crystallization process |
| 01/19/2011 | EP2275416A1 Biologically active methylene blue derivatives |
| 01/19/2011 | EP2275154A1 Antibacterial composition for medical use and medical device |
| 01/19/2011 | EP2275141A1 Tastemasked pharmaceutical compositions |
| 01/19/2011 | EP2275139A1 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID |
| 01/19/2011 | EP2275134A2 Use of ADCC-optimized antibodies for treating weak patients |
| 01/19/2011 | EP2275133A1 Use of bioadhesives and adjuvants for the mucosal delivery of antigens |
| 01/19/2011 | EP2275129A2 Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins |
| 01/19/2011 | EP2275091A1 Pharmaceutical compositions comprising adsorbates of an amorphous drug |
| 01/19/2011 | EP2274427A2 Tat dna sequences, gene constructs, vaccine and processes thereof |
| 01/19/2011 | EP2274335A1 Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes |
| 01/19/2011 | EP2274311A2 Compounds and methods for the treatment of viral infection |
| 01/19/2011 | EP2274293A1 Methods for synthesizing kotalanol and stereoisomers and analogues thereof, and novel compounds produced thereby |
| 01/19/2011 | EP2274290A2 Linear and cyclic guanidine derivatives, method of preparation and uses thereof |
| 01/19/2011 | EP2274281A1 Hcv protease inhibitors |
| 01/19/2011 | EP2274053A2 Use of the human pancreatic polypeptide as a therapeutic agent |
| 01/19/2011 | EP2274042A1 Treatment and/or prevention of multiple sclerosis |
| 01/19/2011 | EP2274006A2 Angiostatic compositions comprising truncated tyrosyl-trna synthetase polypeptides and methods of using same |
| 01/19/2011 | EP2273989A1 Combination therapy for the treatment of bacterial infections |
| 01/19/2011 | EP1919899B1 Macrocyclic inhibitors of hepatitis c virus |
| 01/19/2011 | EP1773867B1 Proteinaceous compounds and uses therefor |
| 01/19/2011 | EP1660121B1 Live attenuated bacterial vaccine |
| 01/19/2011 | EP1644389B1 Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs |
| 01/19/2011 | EP1481969B1 Piperidine derivative compounds and drugs containing the compounds as the active ingredient |
| 01/19/2011 | EP1432416B1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 01/19/2011 | EP1330442B1 Phthalazinone derivatives |
| 01/19/2011 | CN1976930B 6,7,8,9-substituted 1-phenyl-1,5-dihydro-pyrido(3,2-b)indol-2-ones useful as anti-infective pharmaceutical agents |
| 01/19/2011 | CN1355171B Extracting process and usage of general aralic chinensis saponin |
| 01/19/2011 | CN101952321A Recombinant RSV antigens |
| 01/19/2011 | CN101952320A Material with immunogenicity |
| 01/19/2011 | CN101952311A G immunoglobulin used against anthrax toxins |
| 01/19/2011 | CN101952289A Condensed pentacyclic derivatives for use in the treatment of flaviviridae infections |
| 01/19/2011 | CN101952274A Non-nucleoside reverse transcriptase inhibitors |
| 01/19/2011 | CN101951958A Cholesterol derivatives of inhibitors of viral fusion |
| 01/19/2011 | CN101951948A Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
| 01/19/2011 | CN101951945A Compositions and methods for treatment of microbial disorders |
| 01/19/2011 | CN101951922A Preparation for treating intestinal infection comprising oligosaccharides and insoluble cellular material |
| 01/19/2011 | CN101951911A 2-amino purine derivatives and their use as anti-herpetic agents |
| 01/19/2011 | CN101951906A Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of life in lung diseases |
| 01/19/2011 | CN101951897A Use of amidoxime carboxylic acid esters and N-hydroxyguanidine carboxylic acid esters for producing prodrugs |
| 01/19/2011 | CN101951762A Foam stabilizer composition |
| 01/19/2011 | CN101948865A Dual-promoter inducible secretable shuttle plasmid and construction method thereof |
| 01/19/2011 | CN101948851A Duck-origin coronavirus N protein gene, clone method and application thereof |
| 01/19/2011 | CN101948850A Preparation method and application of virus-like particles of dengue viruses |
| 01/19/2011 | CN101948849A Preparation and use of truncated Cap protein of porcine circovirus type 2 |
| 01/19/2011 | CN101948842A Heterometrus spinifer poison antibacterial polypeptide gene and preparation method and application thereof |
| 01/19/2011 | CN101948841A Epitope sequences |
| 01/19/2011 | CN101948839A Antimicrobial peptide gene from pinctada fucata and application |
| 01/19/2011 | CN101948835A Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
| 01/19/2011 | CN101948834A siRNA for treating HBV |
| 01/19/2011 | CN101948816A Vaccine against mumps containing a JERYL-LYNN virus strain |
| 01/19/2011 | CN101948812A Eosinophilic kidney type avian infectious bronchitis virus (IBV) virulent vaccine strain and application thereof |
| 01/19/2011 | CN101948811A Method for expanding antigen spectrum of foot-and-mouth disease vaccine strain by reverse genetic operation and preparation method of vaccine |
| 01/19/2011 | CN101948809A Inactivated vaccine for preventing duck viral hepatitis and preparation method thereof |
| 01/19/2011 | CN101948792A O157:H7 enhancement mucosal immunity multivalence fusion type recombination strain and vaccine |
| 01/19/2011 | CN101948791A Marker-free gene deletion attenuated mutant of vibrio alginolyticus wild strain, related preparation and application |
| 01/19/2011 | CN101948784A Bdellovibrio bacteriovorus preparation and fermentation method and application thereof |
| 01/19/2011 | CN101948716A Anhydrous hand washing agent |
| 01/19/2011 | CN101948566A Multifunctional polymer for resisting fungi and cancers and performing cell imaging and preparation method thereof |
| 01/19/2011 | CN101948546A Fusion protein SAmB as well as coding gene and applications thereof |
| 01/19/2011 | CN101948539A IL-18 binding proteins |
| 01/19/2011 | CN101948536A Porcine transmissible gastroenteritis virus (PTGEV) and porcine epidemic diarrhea virus (PEDV) dual yolk antibody and preparation method thereof |
| 01/19/2011 | CN101948516A Establishment and application of vaccinia virus vector-based reverse genetics system |
| 01/19/2011 | CN101948512A Polypeptide WA8 for inhibiting type-2 shiga toxin activity and coding gene and application thereof |
| 01/19/2011 | CN101948510A Molecular mimic peptide of type O foot and mouth disease virus VP2 epitope and applications thereof |
| 01/19/2011 | CN101948485A Alpha crystal form of tenofovir disoproxil fumarate, and preparation method and application thereof |
| 01/19/2011 | CN101948462A Azaspiroalkene and azaspiroalkane compounds with nicotinic cholinergic receptor activity |
| 01/19/2011 | CN101948442A Preparation method of linezolid and preparation thereof |